Newland Pharmaceutical Co (SZSE:301277) Cash-to-Debt : 784.19 (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Newland Pharmaceutical Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Newland Pharmaceutical Co's cash to debt ratio for the quarter that ended in Sep. 2024 was 784.19.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Newland Pharmaceutical Co could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Newland Pharmaceutical Co's Cash-to-Debt or its related term are showing as below:

SZSE:301277' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13 Med: 131.53 Max: 784.19
Current: 784.19

During the past 6 years, Newland Pharmaceutical Co's highest Cash to Debt Ratio was 784.19. The lowest was 0.13. And the median was 131.53.

SZSE:301277's Cash-to-Debt is ranked better than
93.15% of 1022 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs SZSE:301277: 784.19

Newland Pharmaceutical Co Cash-to-Debt Historical Data

The historical data trend for Newland Pharmaceutical Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Newland Pharmaceutical Co Cash-to-Debt Chart

Newland Pharmaceutical Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.78

0.33

0.34

131.53

316.23

Newland Pharmaceutical Co Quarterly Data
	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial													246.83	316.23	363.28	470.28	784.19

Competitive Comparison of Newland Pharmaceutical Co's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Newland Pharmaceutical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Newland Pharmaceutical Co's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Newland Pharmaceutical Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Newland Pharmaceutical Co's Cash-to-Debt falls into.

Newland Pharmaceutical Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Newland Pharmaceutical Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	859.519	/	(1.991	+	0.727)
	=	316.23

Newland Pharmaceutical Co's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	803.793	/	(1.025	+	0)
	=	784.19

Newland Pharmaceutical Co (SZSE:301277) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Newland Pharmaceutical Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Newland Pharmaceutical Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Newland Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Newland Pharmaceutical Co Ltd (SZSE:301277) » Definitions » Cash-to-Debt

Traded in Other Exchanges

N/A

Address

East side of the south section of Weiwu Road, Henan Province, Changge, CHN, 461500

Website

http://www.newlandpharma.com

Newland Pharmaceutical Co Ltd is engaged in the research and development, production and sales of chiral pharmaceutical intermediates.

Newland Pharmaceutical Co Headlines

No Headlines